– JERSEY, St. Helier – Novocure (NASDAQ: NVCR) today announced the addition of experienced executive leader, Tim Scannell to its board of directors on Feb. 5.
“We are extremely pleased to welcome Tim to our board of directors,” said Executive Chairman, Bill Doyle. “His extensive and impressive background at Stryker, one of the world’s leading medical technology companies, will provide invaluable guidance as we advance product development and prepare for an anticipated period of significant innovation and growth.”
Mr. Scannell has been appointed to the Nominating and Corporate Governance Committee of the Board, effective upon his election to the board.
About Tim Scannell
Mr. Scannell is currently President and COO of Stryker Corporation where he is responsible for all of Stryker’s operating businesses and regions, a position he has held since August 2018.
Before this position, he served as Group President of Stryker’s MedSurg and Neurotechnology group from 2009 to 2018.
He also serves on the board of directors for Insulet Corporation. Mr. Scannell holds bachelor’s and master’s degrees in business administration from the University of Notre Dame.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and liver cancer.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland, Japan, and Israel.
For more information: https://www.novocure.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
